| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
|
Hepatology
|
2013
|
5.03
|
|
2
|
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
|
Hepatology
|
2010
|
3.00
|
|
3
|
Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.
|
Hepatology
|
2013
|
2.36
|
|
4
|
Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
|
J Hepatol
|
2006
|
2.09
|
|
5
|
Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.
|
Hepatology
|
2009
|
1.83
|
|
6
|
Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
|
J Hepatol
|
2008
|
1.76
|
|
7
|
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.
|
Intervirology
|
2005
|
1.71
|
|
8
|
Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts.
|
J Hepatol
|
2006
|
1.65
|
|
9
|
Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis.
|
J Gastroenterol Hepatol
|
2008
|
1.59
|
|
10
|
Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
|
J Hepatol
|
2012
|
1.53
|
|
11
|
Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan.
|
J Gastroenterol
|
2004
|
1.42
|
|
12
|
Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
|
J Gastroenterol
|
2004
|
1.41
|
|
13
|
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
|
J Clin Virol
|
2012
|
1.35
|
|
14
|
IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.
|
J Infect Dis
|
2011
|
1.33
|
|
15
|
Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B.
|
J Gastroenterol Hepatol
|
2005
|
1.26
|
|
16
|
Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.
|
Am J Gastroenterol
|
2011
|
1.21
|
|
17
|
Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.
|
Hepatology
|
2007
|
1.16
|
|
18
|
Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.
|
Hepatology
|
2011
|
1.12
|
|
19
|
Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
|
J Med Virol
|
2007
|
1.10
|
|
20
|
Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
|
J Med Virol
|
2006
|
1.04
|
|
21
|
Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C.
|
Am J Med
|
2007
|
1.00
|
|
22
|
Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.
|
J Gastroenterol
|
2013
|
1.00
|
|
23
|
Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia.
|
Intervirology
|
2007
|
0.99
|
|
24
|
Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.
|
J Clin Virol
|
2009
|
0.99
|
|
25
|
High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma.
|
Cancer
|
2009
|
0.99
|
|
26
|
Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C.
|
J Med Virol
|
2007
|
0.98
|
|
27
|
A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.
|
J Med Virol
|
2009
|
0.97
|
|
28
|
Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis.
|
Cancer
|
2006
|
0.97
|
|
29
|
Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections.
|
J Med Virol
|
2006
|
0.96
|
|
30
|
Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.
|
Intervirology
|
2009
|
0.96
|
|
31
|
Necessities of interferon therapy in elderly patients with chronic hepatitis C.
|
Am J Med
|
2009
|
0.96
|
|
32
|
Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients.
|
Intern Med
|
2008
|
0.96
|
|
33
|
A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients.
|
Dig Dis Sci
|
2006
|
0.95
|
|
34
|
Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.
|
J Med Virol
|
2012
|
0.94
|
|
35
|
Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
|
Intervirology
|
2007
|
0.94
|
|
36
|
Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.
|
J Med Virol
|
2013
|
0.94
|
|
37
|
Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively.
|
Hepatol Res
|
2011
|
0.93
|
|
38
|
Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus.
|
J Med Virol
|
2010
|
0.93
|
|
39
|
Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis.
|
Hepatology
|
2012
|
0.92
|
|
40
|
Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare-up.
|
J Med Virol
|
2005
|
0.91
|
|
41
|
Change of hepatitis B virus genotypes in acute and chronic infections in Japan.
|
J Med Virol
|
2008
|
0.91
|
|
42
|
Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1.
|
J Clin Microbiol
|
2013
|
0.91
|
|
43
|
Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants.
|
Hepatol Res
|
2009
|
0.91
|
|
44
|
Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.
|
Am J Med
|
2006
|
0.91
|
|
45
|
Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.
|
J Gastroenterol
|
2012
|
0.91
|
|
46
|
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy.
|
Intervirology
|
2009
|
0.90
|
|
47
|
Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.
|
J Med Virol
|
2010
|
0.90
|
|
48
|
Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.
|
J Med Virol
|
2009
|
0.89
|
|
49
|
Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
|
J Med Virol
|
2011
|
0.89
|
|
50
|
Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H.
|
J Clin Virol
|
2007
|
0.88
|
|
51
|
Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival.
|
Scand J Gastroenterol
|
2005
|
0.88
|
|
52
|
Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment.
|
Intervirology
|
2012
|
0.88
|
|
53
|
Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan.
|
J Gastroenterol
|
2012
|
0.87
|
|
54
|
Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3cm or less in diameter.
|
Hepatol Res
|
2005
|
0.87
|
|
55
|
Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection.
|
J Gastroenterol
|
2005
|
0.87
|
|
56
|
Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: A preliminary report.
|
Hepatol Res
|
2007
|
0.86
|
|
57
|
Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.
|
Hepatol Res
|
2009
|
0.86
|
|
58
|
Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study.
|
J Gastroenterol
|
2012
|
0.86
|
|
59
|
Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection.
|
J Gastroenterol
|
2012
|
0.86
|
|
60
|
Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy.
|
Intervirology
|
2011
|
0.86
|
|
61
|
Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis.
|
J Gastroenterol
|
2007
|
0.86
|
|
62
|
Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
|
J Med Virol
|
2007
|
0.86
|
|
63
|
Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients.
|
Hepatol Res
|
2011
|
0.86
|
|
64
|
Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
|
Jpn J Clin Oncol
|
2011
|
0.86
|
|
65
|
Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma.
|
Liver Int
|
2008
|
0.86
|
|
66
|
Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.
|
J Med Virol
|
2011
|
0.85
|
|
67
|
Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia.
|
Hepatol Res
|
2009
|
0.85
|
|
68
|
Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy.
|
Intervirology
|
2012
|
0.85
|
|
69
|
Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b.
|
J Med Virol
|
2014
|
0.85
|
|
70
|
Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b.
|
J Med Virol
|
2010
|
0.85
|
|
71
|
HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
|
Liver Int
|
2010
|
0.85
|
|
72
|
Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients.
|
Hepatol Res
|
2012
|
0.84
|
|
73
|
Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma.
|
J Med Virol
|
2008
|
0.84
|
|
74
|
Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma.
|
Hepatol Res
|
2013
|
0.84
|
|
75
|
Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model.
|
Liver Int
|
2011
|
0.84
|
|
76
|
Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin.
|
Hepatol Res
|
2008
|
0.84
|
|
77
|
Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.
|
Intervirology
|
2004
|
0.83
|
|
78
|
Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
|
Oncology
|
2011
|
0.83
|
|
79
|
Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.
|
J Med Virol
|
2006
|
0.83
|
|
80
|
A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
|
J Med Virol
|
2013
|
0.83
|
|
81
|
Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis.
|
World J Gastroenterol
|
2008
|
0.83
|
|
82
|
Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
|
J Gastroenterol Hepatol
|
2009
|
0.83
|
|
83
|
Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL.
|
Hepatol Res
|
2012
|
0.82
|
|
84
|
Potential of a no-touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: An experimental animal study.
|
Hepatol Res
|
2014
|
0.82
|
|
85
|
Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients.
|
J Gastroenterol Hepatol
|
2010
|
0.82
|
|
86
|
Hepatitis B virus-related hepatocellular carcinogenesis and its prevention.
|
Intervirology
|
2005
|
0.82
|
|
87
|
Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis.
|
J Gastroenterol
|
2004
|
0.81
|
|
88
|
Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C.
|
Intern Med
|
2007
|
0.81
|
|
89
|
Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
|
J Med Virol
|
2004
|
0.81
|
|
90
|
Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up.
|
J Gastroenterol
|
2013
|
0.81
|
|
91
|
Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy.
|
Hepatol Res
|
2011
|
0.81
|
|
92
|
Clinical and virological effects of long-term (over 5 years) lamivudine therapy.
|
J Med Virol
|
2010
|
0.81
|
|
93
|
Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients.
|
Am J Med
|
2010
|
0.81
|
|
94
|
Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma.
|
J Med Virol
|
2012
|
0.80
|
|
95
|
Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance.
|
Intervirology
|
2007
|
0.80
|
|
96
|
Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load.
|
Hepatol Res
|
2012
|
0.80
|
|
97
|
Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center.
|
Intervirology
|
2006
|
0.80
|
|
98
|
Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease.
|
Hepatol Res
|
2013
|
0.80
|
|
99
|
Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load.
|
Intervirology
|
2004
|
0.80
|
|
100
|
Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection.
|
J Clin Microbiol
|
2013
|
0.80
|
|
101
|
Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
|
J Med Virol
|
2006
|
0.80
|
|
102
|
Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma.
|
Oncology
|
2016
|
0.80
|
|
103
|
Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C.
|
J Med Virol
|
2013
|
0.80
|
|
104
|
Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
|
Oncology
|
2016
|
0.79
|
|
105
|
Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases.
|
Intervirology
|
2010
|
0.79
|
|
106
|
Origin of neovascular structure in an early stage of hepatocellular carcinoma: study of alpha-smooth muscle actin immunohistochemistry in serial thin sections of surgically resected cancer.
|
J Gastroenterol Hepatol
|
2006
|
0.79
|
|
107
|
Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine.
|
J Med Virol
|
2007
|
0.79
|
|
108
|
Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase.
|
Am J Med
|
2006
|
0.79
|
|
109
|
Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment.
|
Intervirology
|
2005
|
0.79
|
|
110
|
Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C.
|
Intervirology
|
2005
|
0.79
|
|
111
|
Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection.
|
J Gastroenterol
|
2007
|
0.79
|
|
112
|
Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus.
|
Hepatol Res
|
2011
|
0.79
|
|
113
|
The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.
|
Intern Med
|
2011
|
0.79
|
|
114
|
Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer.
|
Hepatol Res
|
2010
|
0.78
|
|
115
|
Prevention of disease progression with anti-inflammatory therapy in patients with HCV-related cirrhosis: a Markov model.
|
Oncology
|
2014
|
0.78
|
|
116
|
Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases.
|
Gut Liver
|
2013
|
0.78
|
|
117
|
Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2.
|
Hepatol Res
|
2007
|
0.78
|
|
118
|
Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients.
|
J Gastroenterol
|
2008
|
0.78
|
|
119
|
Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C.
|
J Med Virol
|
2009
|
0.78
|
|
120
|
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load.
|
Intern Med
|
2010
|
0.78
|
|
121
|
HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy.
|
Liver Int
|
2014
|
0.78
|
|
122
|
Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
|
J Med Virol
|
2008
|
0.78
|
|
123
|
New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma.
|
Hepatol Res
|
2010
|
0.78
|
|
124
|
Efficacy of interferon therapy in elderly patients with chronic hepatitis C.
|
Intervirology
|
2006
|
0.78
|
|
125
|
Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis.
|
J Med Virol
|
2013
|
0.78
|
|
126
|
Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C.
|
Intervirology
|
2008
|
0.78
|
|
127
|
Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C.
|
Intern Med
|
2008
|
0.78
|
|
128
|
The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load.
|
Intern Med
|
2008
|
0.78
|
|
129
|
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.
|
Intern Med
|
2011
|
0.78
|
|
130
|
The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2.
|
Intern Med
|
2009
|
0.77
|
|
131
|
Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment.
|
Intervirology
|
2009
|
0.77
|
|
132
|
Prolonged hepatitis after acute infection with genotype H hepatitis B virus.
|
Intern Med
|
2007
|
0.77
|
|
133
|
Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
|
J Med Virol
|
2005
|
0.77
|
|
134
|
Randomized Controlled Trial Comparing the Efficacy of Impedance Control and Temperature Control of Radiofrequency Interstitial Thermal Ablation for Treating Small Hepatocellular Carcinoma.
|
Oncology
|
2015
|
0.77
|
|
135
|
Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load.
|
Hepatol Res
|
2012
|
0.77
|
|
136
|
Potential of laparoscopy in chronic liver disease with hepatitis B and C viruses.
|
Hepatol Res
|
2008
|
0.77
|
|
137
|
Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine.
|
J Gastroenterol
|
2007
|
0.77
|
|
138
|
Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease.
|
J Med Virol
|
2008
|
0.77
|
|
139
|
Magnetic resonance laparoscopy: A new non-invasive technique for the assessment of chronic viral liver disease.
|
Hepatol Res
|
2013
|
0.76
|
|
140
|
Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load.
|
Intern Med
|
2009
|
0.76
|
|
141
|
Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment.
|
Hepatol Res
|
2009
|
0.76
|
|
142
|
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load.
|
Intern Med
|
2010
|
0.76
|
|
143
|
Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine.
|
J Gastroenterol
|
2013
|
0.76
|
|
144
|
Association of HLA-DR14 with the treatment response in Japanese patients with autoimmune hepatitis.
|
Dig Dis Sci
|
2010
|
0.76
|
|
145
|
The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load.
|
Intern Med
|
2008
|
0.76
|
|
146
|
What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study.
|
Gut Liver
|
2013
|
0.76
|
|
147
|
Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection.
|
J Gastroenterol
|
2006
|
0.76
|
|
148
|
[Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure].
|
Nihon Shokakibyo Gakkai Zasshi
|
2011
|
0.76
|
|
149
|
Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma--direct ablative effects and a long-term outcome.
|
Liver Int
|
2007
|
0.76
|
|
150
|
Usefulness of the serum KL-6 assay in patients with hepatitis C virus.
|
Intervirology
|
2005
|
0.76
|
|
151
|
Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load.
|
Intern Med
|
2008
|
0.76
|
|
152
|
New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan.
|
Hepatol Int
|
2015
|
0.75
|
|
153
|
Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.
|
Intervirology
|
2012
|
0.75
|
|
154
|
Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
|
J Med Virol
|
2005
|
0.75
|
|
155
|
Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels.
|
Scand J Gastroenterol
|
2009
|
0.75
|
|
156
|
Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.
|
Oncology
|
2017
|
0.75
|
|
157
|
Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b.
|
J Med Virol
|
2015
|
0.75
|
|
158
|
New ablation procedure for a radiofrequency liver tissue coagulation system using an expandable needle.
|
Liver Int
|
2007
|
0.75
|
|
159
|
Randomized controlled trial of a new procedure of radiofrequency ablation using an expandable needle for hepatocellular carcinoma.
|
Hepatol Res
|
2013
|
0.75
|
|
160
|
Changes in viral loads of lamivudine-resistant mutants during entecavir therapy.
|
Hepatol Res
|
2007
|
0.75
|
|
161
|
Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin.
|
Intern Med
|
2007
|
0.75
|
|
162
|
Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy.
|
J Med Virol
|
2012
|
0.75
|
|
163
|
Lipiodol and dye at the site of ablation decreases during RFA.
|
Intervirology
|
2009
|
0.75
|
|
164
|
The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load.
|
Intervirology
|
2008
|
0.75
|
|
165
|
Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus.
|
Intervirology
|
2004
|
0.75
|
|
166
|
Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
|
J Med Virol
|
2007
|
0.75
|